Researchers at the University of Florida Shands Cancer Center in Gainesville have received FDA approval for a Phase I trial of Oxi4503, an experimental treatment that damages leukemia cells and eliminates the blood vessels that allow the cells to thrive. The trial will involve patients with acute myelogenous leukemia who are no longer responding to standard treatments.

Related Summaries